Mesalamine in the treatment and maintenance of remission of ulcerative colitis - Wikidata - awgldk - TriplyDB

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

http://www.wikidata.org/entity/Q26865546

about

Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Five-aminosalicylic Acid: an update for the reappraisal of an old drug Development and validation of an LC-MS/MS method for the determination of mesalazine in beagle dog plasma and its application to a pharmacokinetic study.Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity Indian Society of Gastroenterology consensus on ulcerative colitis.Immunosuppressive and biologic therapy for ulcerative colitis.Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.Natural Nuclear Factor Kappa Beta Inhibitors: Safe Therapeutic Options for Inflammatory Bowel Disease.Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.Regulatory framework on bioequivalence criteria for locally acting gastrointestinal drugs: the case for oral modified release mesalamine formulations.Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.Mesalazine-induced myocarditis: a case report.NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.

P2860

Q26747744-8316E548-6F84-4ABE-8C19-803EEB11CF67 Q26801119-2F43A4D0-9E01-44F5-A35D-F38737B97849 Q34062169-724904BB-B3CA-4186-97D0-367B9A4EB694 Q34273329-30FE66B9-86BA-4771-AEC0-FEEE6D381A14 Q35061210-6C724DE6-99EE-438F-B7B7-857EA5CC780D Q35187345-B9333745-2B9C-4467-A85C-66294A2F109E Q36084796-3714F096-05A7-426B-82D7-55F1CC4F122A Q38055371-DBCEBFAD-9172-42C7-B79A-087F2C1F95B4 Q38060831-6CBE5B94-F0BA-4B99-8B45-EA2A05E02241 Q38396153-1F6E2D2A-1B5E-4426-8783-B556EF0FC3D9 Q38571099-2E9F6A46-7923-40CF-9A03-C3D38423F3F6 Q38683067-F1D6D050-934B-4D6C-92C7-67DEAC491043 Q38973323-E882E025-9E2E-42A2-8286-5C61D6B39652 Q39401950-FBDB6B61-69D9-4931-9CB2-0B8D6D24184C Q42602745-43073172-5DDA-492F-AC48-1ACF814704FE Q43834227-E9EF403A-BEBE-41C9-84CF-A90D682AF726 Q50284494-517399B4-C00F-41B1-ACDB-95111EC4233D Q55427997-674F9B39-24D9-4097-9452-CAF1416F1594

P2860

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

http://www.wikidata.org/entity/Q26865546

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

@ast

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

@en

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

@nl

type

label

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

@ast

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

@en

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

@nl

prefLabel

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

@ast

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

@en

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

@nl

P1433

Q26865546-3EA5F7CA-EF83-4C04-8DE1-20E2D9563B6E

P1476

Q26865546-796EEDA2-8F7E-409B-93C9-BAC5E0BCA7A4

P2093

Q26865546-31BB31D9-1E42-4C8F-A1F9-FB8433637361

Q26865546-CC7437F5-04AB-443D-B699-92245E4242AA

P2860

Q26865546-01CDEAC8-92A8-4EEE-9C93-7FEC39B4DB91

Q26865546-07FF348B-1301-4928-9FB5-401B6A6B92A8

Q26865546-084A750C-2D4B-472F-B8E4-9C0AF9EAE9CC

Q26865546-09499C5A-00BD-4CB5-A7B9-9C3C856C93D1

Q26865546-0C986F3A-00A4-4551-B2EC-09AB894A297F

Q26865546-147D9CEA-A6A4-41D1-9D46-26894B02FF1C

Q26865546-19072F94-360E-4FBB-BA2C-B8F8E2CFB4F7

Q26865546-1C062242-803A-418C-84BF-88D854432A6D

Q26865546-2009F522-ACEF-4349-B392-9DE10D083978

Q26865546-202A125D-500C-4F44-A99C-EEF7DECCD5D0

P304

Q26865546-D9EE3186-CB6A-4BED-ADEE-F80CA2D15666

P31

Q26865546-1D28B45B-1FFB-49DF-AF58-8449F1D5FBEB

P3181

Q26865546-F1AF5F9B-37FC-4E3A-84E9-EFEF4931B3EE

P356

Q26865546-C1AB201C-2607-462C-BD3A-13FA2F2F623F

P407

Q26865546-4FC74638-0EFD-420B-A874-4D0FED67587D

P433

Q26865546-93E47011-91A1-44DD-AF33-61D27B00C7EB

P478

Q26865546-7D85DA0F-AAEF-408A-B635-53091F6C0D86

P577

Q26865546-3F9EFF92-AA96-44FF-9944-7EC797443A93

P5875

Q26865546-A7E7C941-76C7-49A2-AAF7-3A74889C654B

P698

Q26865546-15A2F86A-C397-41C4-9FE6-872D9E00ED0A

P932

Q26865546-2CFBF058-CE02-40F7-9140-28857D7452F4

P3181

P356

P1433

Expert Review of Clinical Pharmacology

P1476

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

@en

P2093

Alan C Moss

http://www.w3.org/2001/XMLSchema#string

Maggie Ham

http://www.w3.org/2001/XMLSchema#string

P2860

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis

Environmental phthalate exposure in relation to reproductive outcomes and other health endpoints in humans

Medications as a source of human exposure to phthalates

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

Association between prenatal exposure to phthalates and the health of newborns.

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.

European evidence-based Consensus on the management of ulcerative colitis: Current management.

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.

P304

113-23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1489800

http://www.w3.org/2001/XMLSchema#string

P356

10.1586/ECP.12.2

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221888221

http://www.w3.org/2001/XMLSchema#string

P698

22390554

http://www.w3.org/2001/XMLSchema#string

P932

3314328

http://www.w3.org/2001/XMLSchema#string